ProCE Banner Activity

PARP Inhibitors for Prostate Cancer: Expert Answers to Your Questions

Clinical Thought

Daniel P. Petrylak, MD, answers healthcare professionals’ questions on leveraging PARP inhibitor–based therapies for prostate cancer, including gene differences in sensitivity to PARP inhibition, when to repeat somatic testing, and how to choose between approved PARP inhibitor combination regimens.

Released: April 09, 2024

Expiration: April 08, 2025

Share

Faculty

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Faculty Disclosure

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Exelixis, Gilead, Incyte, Infinity, Ipsen, Janssen, Lilly, Merck, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi Aventis, Seattle Genetics, UroGen; researcher: Ada Cap, Agensys, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Eisai, Endocyte, Ferring, Genentech, Gilead, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics.